Currently, there are multiple preclinical and clinical trials testing biosafety, tumor specificity and effectiveness of anti-CD47 antibodies, anti-SIRPα antibodies and SIRPα-Fc fusion proteins [reviewed in (246)]. This evidence concerns the gene SIRPA and neoplasm.